{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'liver event follow up assessments within 24', 'remedies, other over the counter', 'hrs', 'medications.', 'Monitor subjects twice weekly until liver', 'Record alcohol use on the liver event', 'chemistries resolve, stabilize or return to', 'alcohol intake case report form', 'within normal ranges.', 'A specialist or hepatology consultation is', 'For bilirubin or INR criteria:', 'recommended', 'For All other criteria:', 'Anti-nuclear antibody, anti-smooth muscle', 'antibody, Type 1 anti-liver kidney', 'Repeat liver chemistries (include ALT, AST,', 'microsomal antibodies, and quantitative', 'alkaline phosphatase, bilirubin) and perform', 'total immunoglobulin G (lgG or gamma', 'liver event follow up assessments within 24-', 'globulins).', '72 hrs', 'Serum acetaminophen adduct HPLC', 'Monitor subjects weekly until liver', 'assay (quantifies potential acetaminophen', 'chemistries resolve, stabilize or return to', 'contribution to liver injury in subjects with', 'within normal ranges.', 'definite or likely acetaminophen use in the', 'preceding week [James, 2009]). NOTE:', 'not required in China', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy CRF forms.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that subject if ALT > 3xULN and bilirubin 2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2. All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to subjects receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'PK sample may not be required for subjects known to be receiving placebo or non-GSK comparator treatments.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to', \"blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject's best\", 'approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in', 'the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in', 'the SRM.', '70']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.3.', 'Appendix 3: Genetic Research', 'Genetics - Background', 'Naturally occurring genetic variation may contribute to inter-individual variability in', \"response to medicines, as well as an individual's risk of developing specific diseases.\", 'Genetic factors associated with disease characteristics may also be associated with', 'response to therapy, and could help to explain some clinical study outcomes. For', 'example, genetic variants associated with age-related macular degeneration (AMD) are', 'reported to account for much of the risk for the condition [Gorin, 2012] with certain', 'variants reported to influence treatment response [Chen, 2012]. Thus, knowledge', 'of', 'the', 'genetic etiology of disease may better inform understanding of disease and the', 'development of medicines. Additionally, genetic variability may impact the', 'pharmacokinetics (absorption, distribution, metabolism, and elimination), or', 'pharmacodynamics (relationship between concentration and pharmacologic effects or the', 'time course of pharmacologic effects) of a specific medicine and/or clinical outcomes', '(efficacy and/or safety) observed in a clinical study.', 'Genetic Research Objectives and Analyses', 'The objectives of the genetic research are to investigate the relationship between genetic', 'variants and:', 'Response to medicine, including any concomitant medicines;', 'COPD susceptibility, severity, and progression of related conditions', 'Genetic data may be generated while the study is underway or following completion of', 'the study. Genetic evaluations may include focused candidate gene approaches and/or', 'examination of a large number of genetic variants throughout the genome (whole genome', 'analyses). Genetic analyses will utilize data collected in the study and will be limited to', 'understanding the objectives highlighted above. Analyses may be performed using data', 'from multiple clinical studies to investigate these research objectives.', 'Planned analyses and results of genetic investigations will be reported either as part of the', 'clinical RAP and study report, or in a separate genetics RAP and report, as appropriate.', 'Study Population', 'Any subject who is enrolled in the study can participate in genetic research. Any subject', 'who has received an allogeneic bone marrow transplant must be excluded from the', 'genetic research.', 'Study Assessments and Procedures', 'A key component of successful genetic research is the collection of samples during', 'clinical studies. Collection of samples, even when no a priori hypothesis has been', 'identified, may enable future genetic analyses to be conducted to help understand', 'variability in disease and medicine response.', '71']\n\n###\n\n", "completion": "END"}